James Love's blog
I was asked recently to look at some data on employment in the copyright industry. This addresses one set of data points, the BLS estimates of US employment in the Sound Recording Industries.
Occupational Employment Statistics
NAICS 2-Digit Industry Specific Estimates, May 2010
51 Information 2,708,760
NAICS 3-Digit Industry Specific Estimates, May 2010
511 Publishing Industries, except Internet, 758,090, 28.0%
512 Motion Picture and Sound Recording Industries, 371,450, 13.7%
515 Broadcasting (except internet), 292,010, 10.8%
517 Telecommunications, 909,780, 33.6%
Pictures from the WIPO SCCR negotiations on a treaty for persons who are blind or have other disabilitiesSubmitted by James Love on 19. June 2011 - 7:58
In a major breakthrough on the WIPO negotiations on copyright exceptions for persons with disabilities, at around 1pm today, a non-paper "resulting from informal discussions among Argentina, Brazil, Ecuador, the European Union and its Member States, Mexico, Paraguay and the United States of America" was distributed at the WIPO SCCR 22.
A copy of the document is available here:
|Members of the WBU delegation at WIPO SCCR 22|
June 16, 10 am: There are good news and less good news to report from Geneva. While overall, things have moved in positive directions, with the US and the EU engaged in very constructive negotiations with Brazil and other treaty sponsors, there are still many frustrations.
White House and European Commission trade official oppose waiver of drug patents for Least Developed Countries (LDCs)Submitted by James Love on 11. June 2011 - 9:36
KEI Policy Brief 2011:1
June 11, 2011, Revised August 15, 2011
Using industry assertions of R&D spending, pharmaceutical related R&D spending by the private sector was less than 8 percent of global sales in 2010.
These are the data:
2010 Global R&D by all private companies: - $67.4 billion
Source: Page 2 of the 2011 PhRMA industry profile
2010 Global sales - $856 billion
KEI Intervention at UN HLM on HIV: De-Linking R&D costs from drug prices and the sustainability of treatmentSubmitted by James Love on 9. June 2011 - 4:43
These are the notes from my intervention today at the UN's High Level Meeting on HIV/AIDS in New York. The persons making statements from the floor were asked to keep their comments to two minutes, so the actual intervention was somewhat shorter. Jamie
the comprehensive review of the progress achieved in realizing
the Declaration of Commitment on HIV/AIDS and
NYC, 7 PM Wed, June 8, 2011.
Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countriesSubmitted by James Love on 27. May 2011 - 16:15
KEI has received a copy of a May 16, 2011 letter from Karl De Gucht to Andris Piebalgs, which discusses (1) the EU-India FTA, and (2) Relations between IPR and development policies.
Senator Sanders introduces two medical innovation prize bills in U.S. Senate to de-link R&D costs from drug pricesSubmitted by James Love on 27. May 2011 - 4:53
This is the statement that was delivered by Karin L. Ferriter (from USPTO and USTR), at a UNITAID side event on the Medicines Patent Pool, during a break of the WIPO Standing Committee on the Law of Patents.
Statement on Medicines Patent Pool Side Event
NGO Statement on WHO governance and the Management of Conflicts of Interest and the Future of Financing for WHOSubmitted by James Love on 18. May 2011 - 2:07
NGO Statement on WHO governance and the Management of Conflicts of Interest and the Future of Financing for WHO.
May 18, 2011
We write to express our concerns about governance of the World Health Organization (WHO) and other public health bodies, as regards the management of conflicts of interest.
During today's discussion at the WIPO Standing Committee on the Law of Patents (SCP) on patent quality KEI make four points in its intervention.
1. WIPO should consider gathering information on the costs of litigation to challenge the validity of patents.
2. WIPO should consider creating a database to share information on the cases where litigation has resulted findings that patent claims as invalid.
On April 19, 2011, Dr Kumariah Balasubramaniam died at his home in Sri Lanka. Dr. Balasubramaniam, known to many as Dr. Bala, was described by Professor Colvin Gooneratne as "one of the most knowledgeable, resolute, articulate, versatile, resilient and in many other ways exceptionally brilliant health activists [the world] has produced." My tribute to Dr. Bala is in the Huffington Post. Prof.